CD274 and neoplasm: Treatment of GBC patients with PD-1/PD-L1 inhibitors has emerged as a promising strategy for targeted therapies (Table 2).244,245 TMB-H and MSI-H are potentially useful for assessing neoantigen presentation and viability of immune checkpoint inhibition.246,247 Weinberg et al.248 reported that PD-L1 overexpression was seen on GBC tumor cells from 19 of 237 (8.0%) tumors using IHC.